Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics, Inc. (PTGX) is a healthcare company (biotechnology) based in the United States. The share price is $124.20, down 0.50% on the day, which values the company at $8.11B. Price as of 17 Nov 2026, 19:23 UTC, from Yahoo Finance.

Key facts

Share price
$124.20−0.50% today
Market value
$8.11B
P/E ratio
26.3×last 12 months
Forward P/E
353.5×
Funk Score
49/100
Against its own history
Well above its usual priceusual price $26.65
200-week average
$56.21121% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Protagonist Therapeutics, Inc. in more detail

PTGX trades at 26.3× its last twelve months' earnings, 353.5× next year's expected earnings, 14.7× sales. Measured against its own history, the price is 366% above what its usual multiples would imply ($26.65) — well above its usual price. It sits 121% above its 200-week average of $56.21.

Over the last five fiscal years Protagonist Therapeutics, Inc. has compounded revenue 10.0% a year. Its Funk Score is 49 out of 100 (financial strength 8.3, profitability 4.2, growth 6.5, value 0.4, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Heavy stock-based pay.

3 of the superinvestors tracked here hold PTGX, including Andrew Spokes (4.7% of the portfolio), Stanley Druckenmiller (0.6% of the portfolio), Polen Capital team (0.0% of the portfolio).

Superinvestors holding PTGX

3 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:PTGX vs KRYS (Protagonist Therapeutics, Inc. vs Krystal Biotech)PTGX vs TWST (Protagonist Therapeutics, Inc. vs Twist Bioscience)PTGX vs PRAX (Protagonist Therapeutics, Inc. vs Praxis Precision Medicines)PTGX vs TXG (Protagonist Therapeutics, Inc. vs 10x Genomics)PTGX vs HQY (Protagonist Therapeutics, Inc. vs HealthEquity)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Protagonist Therapeutics, Inc. (PTGX): questions and answers

What is PTGX's P/E ratio?

Protagonist Therapeutics, Inc. trades at 26.3× its last twelve months' earnings and 353.5× next year's expected earnings.

What is Protagonist Therapeutics, Inc.'s market cap?

Protagonist Therapeutics, Inc. is valued at $8.11B at a share price of $124.20.

Is PTGX overvalued or undervalued?

Against its own history, PTGX is well above its usual price: the price is 366% above the $26.65 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is PTGX above its 200-week moving average?

Yes. PTGX is 120.9% above its 200-week average of $56.21. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Protagonist Therapeutics, Inc. growing?

Over the last five fiscal years Protagonist Therapeutics, Inc.'s revenue grew 10.0% a year.

Does PTGX pay a dividend?

Protagonist Therapeutics, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Protagonist Therapeutics, Inc. (PTGX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/PTGX

Underlying data: Yahoo Finance; company filings with the SEC.